Equities researchers at Leerink Partnrs reduced their FY2025 earnings estimates for ICON Public in a research report issued ...
Leerink analyst Faisal A. Khurshid initiated coverage of Nurix Therapeutics (NRIX) with a Market Perform rating and $16 price target The firm notes the company is developing early-stage protein ...
Hosted on MSN1mon
AbbVie Stock Rises After Leerink Partners Upgrades Its RatingAbbVie’s ABBV shares rose 3.0% on Friday after Leerink Partners analyst ... pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human ...
Leerink analyst Roanna Ruiz initiated coverage of CorMedix (CRMD) with an Outperform rating and $18 price target The firm believes the company’s lead product DefenCath represents a significant ...
On Wednesday, Leerink Partners adjusted their financial outlook on Cencora Inc (NYSE: COR), increasing the price target to $301 from the previous $287 while keeping an Outperform rating on the stock.
Launched in October by Leerink Partners, CPE evaluates the long-term societal impact of healthcare innovations, aiming to go beyond typical cost-effectiveness models by assessing therapies not ...
including without limitation those related to our upcoming presentation at the Leerink Partners Global Healthcare Conference and our future prospects, developments and strategies. The forward ...
today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference: Audio webcasts and replays of available presentations will be accessible ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback